| Trial ID: | L4621 |
| Source ID: | NCT06348706
|
| Associated Drug: |
Dipeptidyl Peptidase 4 (Dpp-4) Inhibitor
|
| Title: |
Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 1|NASH
|
| Interventions: |
DRUG: Dipeptidyl peptidase 4 (DPP-4) inhibitor
|
| Outcome Measures: |
Primary: Number of participants with treatment-related effect on NASH status in adolescents with type 1 diabetes mellitus, Effect of DPP-4 inhibitors on NASH in adolescents with type 1 diabetes mellitus measured by Doppler ultrasound and transient elastography with controlled attenuation parameter (CAP) to assess liver stiffness and steatosis stage., 6 months | Secondary: Number of participants with treatment-related Matrix metalloproteinase-14 (MMP-14) level change, Effect of (DPP-4) inhibitors supplementation on Matrix metalloproteinase-14 (MMP-14, (ng/mL) level, 6 months|Number of participants with treatment-related Glycemic control (HbA1c%) level change, Effect of Dipeptidyl peptidase-4 (DPP-4) inhibitors on glycemic control (HbA1c%), 6 months
|
| Sponsor/Collaborators: |
Sponsor: Ain Shams University
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2022-11-10
|
| Completion Date: |
2024-01-15
|
| Results First Posted: |
|
| Last Update Posted: |
2024-04-05
|
| Locations: |
Nancy Elbarbary, Cairo, 11361, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT06348706
|
